Nutraferon ECOMERON S Injection

Plain Nutraferon ECOMERON INJ contains Meropenem (1000 mg) alone, whereas Nutraferon ECOMERON S INJ combines Meropenem (1000 mg) with Sulbactam (500 mg) for a total of 1.5 g. Sulbactam adds irreversible beta-lactamase inhibition and direct bactericidal activity against Acinetobacter baumannii, a major cause of ICU ventilator-associated pneumonia and bloodstream infections.

Unlike clavulanic acid or tazobactam, Sulbactam possesses direct intrinsic antibacterial activity against Acinetobacter species by binding directly to their cell-wall penicillin-binding proteins, producing synergistic killing when paired with Meropenem.

No. Because it contains Meropenem, co-administration with valproic acid or divalproex sodium precipitously lowers serum valproate concentrations (by 60–90%), risking breakthrough seizures.

Yes. Both Meropenem and Sulbactam are eliminated primarily through the kidneys (~70–80%). Your nephrologist or critical care physician will adjust the dose and interval based on Creatinine Clearance (CrCl) and schedule doses after hemodialysis sessions.

Clinicians monitor for hypersensitivity reactions (rash, urticaria, anaphylaxis), infusion-site phlebitis, transient hepatic enzyme elevations, Clostridioides difficile-associated diarrhea, and CNS excitability if renal doses are not adjusted.